Baird raised the firm’s price target on Inspire Medical (INSP) to $180 from $125 and keeps an Outperform rating on the shares. The firm updated its model following its meetings with management.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Teradyne upgraded, Circle Internet initiated: Wall Street’s top analyst calls
- Inspire Medical downgraded to Equal Weight at Morgan Stanley on slowing growth
- Inspire Medical downgraded to Equal Weight from Overweight at Morgan Stanley
- Truist upgrades Inspire Medical to Buy after positive reimbursement ‘surprise’
- Inspire Medical upgraded to Buy from Hold at Truist